Tiiz Therapeutics

Tiiz Therapeutics is a biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors targeting GRP94 (endoplasmin). GRP94 is a specialized chaperone in the endoplasmic reticulum that is essential for the folding and secretion of proteins involved in cancer growth and immune suppression. The company's lead candidates are designed to selectively inhibit GRP94 while sparing other HSP90 isoforms, potentially offering a superior safety profile and enhanced efficacy in treating solid tumors. Tiiz Therapeutics' research is rooted in deep expertise in protein folding and tumor immunology, particularly the role of chaperones in the tumor microenvironment. By disrupting the maturation of key oncogenic drivers, the company aims to provide new therapeutic options for patients with advanced cancers. The company is currently in the pre-clinical stage, advancing its lead programs toward IND-enabling studies.